Bedrijfsoverzicht
ProQR Therapeutics N.V. is a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel therapeutic medicines, specifically leveraging its proprietary Axiomer RNA editing technology to address genetic disorders with significant unmet medical needs. The company operates within the healthcare sector and functions specifically in the biotechnology industry, a field characterized by high research and development costs and a focus on innovative drug candidates rather than established consumer products. At present, the organization employs a workforce of 186 individuals and maintains a total market capitalization of $194.92 million while generating annual revenue of $16.35 million over the trailing twelve-month period. These valuation and revenue figures indicate that ProQR Therapeutics is a mid-sized biotechnology entity that has achieved limited commercial revenue relative to its development stage, reflecting the typical financial profile of companies transitioning from research phases to potential market entry.
Financiële gezondheid
Over the trailing twelve months, the company reported revenue of $16.35 million, yet it recorded a net income loss of $42.18 million and an EBITDA of $-42.54 million, a disparity that reveals a substantial operating cost structure where expenses significantly outweigh commercial earnings before tax and interest. This negative financial position is further evidenced by a free cash flow of $-32.04 million, which indicates that the company is currently burning cash to fund its operations and development pipeline rather than generating liquidity from its current business model. The margin analysis highlights a gross margin of 100.0%, suggesting that the company's direct costs of goods sold are minimal or fully offset, likely due to the pre-revenue nature of its product candidates, while the operating margin stands at -192.9% and the profit margin at -258.1%, both of which signify severe operational losses driven by heavy investment in research, development, and general administrative overhead. Regarding liquidity, the company holds $92.41 million in cash against $15.96 million in debt, creating a robust cash position that exceeds obligations, although the debt-to-equity ratio of 32.33 suggests a leveraged balance sheet structure relative to its equity base. The current ratio is reported at 3.09, indicating a strong ability to cover short-term liabilities with short-term assets, which provides a buffer for ongoing operational needs despite the lack of positive earnings. Furthermore, the return on equity is -61.2% and the return on assets is -19.3%, metrics that demonstrate management is currently unable to generate positive returns on shareholder capital or total assets due to the high levels of accumulated losses inherent in the clinical-stage biotechnology sector.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio of N/A due to the lack of earnings, while the forward P/E is listed at -3.94, implying that the market prices the stock based on future earnings expectations that have not yet been realized or are currently negative. The price-to-book ratio is 3.42, which indicates that the market values the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property, the Axiomer platform, and potential future pipeline assets that are not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 11.92 and an EV/EBITDA of -2.79 suggest that investors are pricing the stock based on its revenue generation potential and asset base rather than current profitability, a common practice for clinical-stage biotechs. The stock has exhibited a price range between a 52-week low of $1.08 and a 52-week high of $3.10, providing a context for recent trading activity within this defined volatility band. The beta value of 0.09 indicates that the stock's price movements are highly uncorrelated with the broader market, suggesting that its price is driven primarily by company-specific developments in its drug pipeline rather than general market sentiment or macroeconomic factors.
Growth & Income
The company has demonstrated a revenue growth rate of 6.1% year-over-year, whereas earnings growth is listed as N/A due to the persistent net losses, indicating that top-line expansion is occurring while the bottom-line profitability remains elusive. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that the firm retains all of its earnings—or rather, all of its capital—to reinvest into research and development activities rather than distributing income to shareholders. This strategic choice to forgo dividends is standard for clinical-stage biotechnology firms that require capital allocation toward advancing their lead product candidate, AX-081, and other therapeutic programs through clinical trials. The overall growth and income profile for ProQR Therapeutics N.V. is characterized by modest revenue expansion coupled with significant cash consumption and zero current income distribution to investors.